Given that MPN patients with concurrent JAK2 and IDH mutations are at high risk for disease progression and have adverse clinical outcomes, we tested whether JAK2 inhibition, IDH2 inhibition, or combined JAK2/IDH2 inhibition would show efficacy in treating Jak2/Idh2-mutant MPN. Here, JAK2 is linked to myeloproliferative neoplasm.